Cargando…
The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes
Atherosclerotic cardiovascular disease (CVD) is the major cause of morbidity and mortality in individuals with diabetes mellitus (DM). Preclinical models have suggested that excessive oxidative stress and hyperglycemia are directly responsible for this pathological association. However, numerous cli...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796233/ https://www.ncbi.nlm.nih.gov/pubmed/33396615 http://dx.doi.org/10.3390/ijms22010287 |
_version_ | 1783634633821257728 |
---|---|
author | Somer, Shmuel Levy, Andrew P. |
author_facet | Somer, Shmuel Levy, Andrew P. |
author_sort | Somer, Shmuel |
collection | PubMed |
description | Atherosclerotic cardiovascular disease (CVD) is the major cause of morbidity and mortality in individuals with diabetes mellitus (DM). Preclinical models have suggested that excessive oxidative stress and hyperglycemia are directly responsible for this pathological association. However, numerous clinical trials involving the administration of high doses of the antioxidant vitamin E or attempts at strict glycemic control have failed to show a significant reduction of CVD in DM patients. We describe here a possible explanation for the failure of these trials, that being their lack of proper patient selection. The haptoglobin (Hp) genotype is a major determinant of the risk of CVD in the setting of DM. Treatment of individuals with the high-risk Hp genotype with antioxidants or aggressive glycemic control has shown benefit in several small studies. These studies suggest a precision medicine-based approach to preventing diabetes complications. This approach would have a profound effect on the costs of diabetes care and could dramatically reduce morbidity from diabetes. |
format | Online Article Text |
id | pubmed-7796233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77962332021-01-10 The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes Somer, Shmuel Levy, Andrew P. Int J Mol Sci Review Atherosclerotic cardiovascular disease (CVD) is the major cause of morbidity and mortality in individuals with diabetes mellitus (DM). Preclinical models have suggested that excessive oxidative stress and hyperglycemia are directly responsible for this pathological association. However, numerous clinical trials involving the administration of high doses of the antioxidant vitamin E or attempts at strict glycemic control have failed to show a significant reduction of CVD in DM patients. We describe here a possible explanation for the failure of these trials, that being their lack of proper patient selection. The haptoglobin (Hp) genotype is a major determinant of the risk of CVD in the setting of DM. Treatment of individuals with the high-risk Hp genotype with antioxidants or aggressive glycemic control has shown benefit in several small studies. These studies suggest a precision medicine-based approach to preventing diabetes complications. This approach would have a profound effect on the costs of diabetes care and could dramatically reduce morbidity from diabetes. MDPI 2020-12-30 /pmc/articles/PMC7796233/ /pubmed/33396615 http://dx.doi.org/10.3390/ijms22010287 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Somer, Shmuel Levy, Andrew P. The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes |
title | The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes |
title_full | The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes |
title_fullStr | The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes |
title_full_unstemmed | The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes |
title_short | The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes |
title_sort | role of haptoglobin polymorphism in cardiovascular disease in the setting of diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796233/ https://www.ncbi.nlm.nih.gov/pubmed/33396615 http://dx.doi.org/10.3390/ijms22010287 |
work_keys_str_mv | AT somershmuel theroleofhaptoglobinpolymorphismincardiovasculardiseaseinthesettingofdiabetes AT levyandrewp theroleofhaptoglobinpolymorphismincardiovasculardiseaseinthesettingofdiabetes AT somershmuel roleofhaptoglobinpolymorphismincardiovasculardiseaseinthesettingofdiabetes AT levyandrewp roleofhaptoglobinpolymorphismincardiovasculardiseaseinthesettingofdiabetes |